ImmunityBio Inc Ordinary Shares IBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IBRX is a good fit for your portfolio.
News
-
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
-
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva
-
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
-
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
-
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
-
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
-
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
-
ImmunityBio Shares Rally as FDA Accepts N-803 Resubmission
Trading Information
- Previous Close Price
- $5.10
- Day Range
- $4.93–5.49
- 52-Week Range
- $1.25–6.93
- Bid/Ask
- $5.39 / $5.41
- Market Cap
- $3.68 Bil
- Volume/Avg
- 2.1 Mil / 4.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4,047.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 628
- Website
- https://www.immunitybio.com
Comparables
Valuation
Metric
|
IBRX
|
ACLX
|
EQRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 5.69 | 0.97 |
Price/Sales | 4,047.42 | 23.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
IBRX
|
ACLX
|
EQRX
|
---|---|---|---|
Quick Ratio | 4.63 | 5.94 | 18.43 |
Current Ratio | 5.05 | 6.06 | 18.78 |
Interest Coverage | −3.53 | −23.39 | — |
Quick Ratio
IBRX
ACLX
EQRX
Profitability
Metric
|
IBRX
|
ACLX
|
EQRX
|
---|---|---|---|
Return on Assets (Normalized) | −125.30% | −6.26% | −15.72% |
Return on Equity (Normalized) | — | −12.08% | −16.71% |
Return on Invested Capital (Normalized) | −157.68% | −13.11% | −21.31% |
Return on Assets
IBRX
ACLX
EQRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qrfcwcnns | Jzlf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ltgncvkyv | Kkzlt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gbqqlgc | Qxpfn | $97.8 Bil | |
MRNA
| Moderna Inc | Kqtxzbby | Rjgg | $38.8 Bil | |
ARGX
| argenx SE ADR | Xxkskhvsl | Zvjv | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Qvnnzfw | Hwjk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Htjdknsfw | Qrbxsx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hrwxldl | Zmcmrn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jzrvpngcm | Swyhk | $12.5 Bil | |
INCY
| Incyte Corp | Fjjtyllxx | Bfhxfl | $11.5 Bil |